English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/61907
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Novel tyrosine kinase inhibitors in the treatment of cancer

AuthorsOcaña, Alberto; Pandiella, Atanasio
Issue Date2009
PublisherBentham Science Publishers
CitationCurrent Drug Targets 10(6): 575-576 (2009)
AbstractIn summary, multi-TK inhibitors are being designed to target multiple activated kinases. The future design plan for these compounds should take into consideration the activated array of kinases in a given tumor. This undoubtedly will increase the efficacy, also avoiding toxicity. Furthermore, irreversible TK inhibitors show more efficacy than reversible ones, with a similar toxicity profile, thereby presenting these inhibitors as attractive alternatives to reversible inhibitors. In addition, irreversible inhibitors may offer advantages with respect to their ability to be more efficacious to fight avoid resistance due to secondary mutations. The development of multikinase, reversible, irreversible, and other allosteric inhibitors of tyrosine kinases is clearly widening the armamentarium to fight neoplastic diseases, and will allow better targeting of the tumoral cells, improved toxicological properties, and more favourable responses by preventing drug resistance.
Identifiersdoi: 10.2174/138945009788488378
issn: 1389-4501
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
Novel Tyrosine.pdf14,07 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.